Koentjoro Sara Listyani, Artini Widya, Soebijantoro Iwan, Istiantoro Vira Wardhana, Rusmayani Emma, Sulastiwaty Rini, Djamal Zeiras Eka, Akbar Arini Safira Nurul, Yoserizal Muhammad
Glaucoma Division, Jakarta Eye Center Hospital, West Jakarta, Special District Region of Jakarta 11520, Indonesia.
Int J Ophthalmol. 2020 Dec 18;13(12):1908-1914. doi: 10.18240/ijo.2020.12.10. eCollection 2020.
To compare surgical results of the Ahmed and Baerveldt implant procedures in glaucoma patients at 1y follow-up at Jakarta Eye Center (JEC) Eye Hospitals.
This cohort retrospective study was conducted on glaucoma patients aged ≥18y who had undergone Ahmed and Baerveldt implant surgery. Intraocular pressure (IOP), visual acuity, glaucoma medication, success rate, early and late postoperative complications, and the number of resurgeries were analyzed.
A total of 351 eyes in the Ahmed group and 94 eyes in the Baerveldt group were included in this study. At 1y follow-up, the mean IOP was found to be significantly lower in the Baerveldt group (13±4.47 mm Hg) compared to the Ahmed group (15.02±5.73 mm Hg; =0.025). Glaucoma medication was required in both the Ahmed and Baerveldt groups (58.92% 71.67%). Comparable success rate was found in both groups. The Ahmed group revealed a complete and qualified success of 86.82%, and failure of 13.17%. Similarly, the Baerveldt group showed complete and qualified success in 87.75% and failure in 12.25% cases. In the Ahmed group, 11.97% early complications, 26.06% late complications and 9.97% resurgeries were observed. In comparison, in the Baerveldt group, 23.40% early complications, 30.95% late complications and 11.70% resurgeries were observed.
Both groups of glaucoma implants show significant IOP reduction, however, the Baerveldt implant group demonstrates greater IOP reduction with more failure rates and complications than the Ahmed implant group.
比较雅加达眼科中心(JEC)眼科医院青光眼患者接受艾哈迈德(Ahmed)和贝尔维尔德(Baerveldt)植入手术1年随访后的手术效果。
对年龄≥18岁且接受过艾哈迈德和贝尔维尔德植入手术的青光眼患者进行这项队列回顾性研究。分析眼压(IOP)、视力、青光眼药物治疗、成功率、术后早期和晚期并发症以及再次手术的次数。
本研究纳入了艾哈迈德组的351只眼和贝尔维尔德组的94只眼。在1年随访时,发现贝尔维尔德组的平均眼压(13±4.47毫米汞柱)明显低于艾哈迈德组(15.02±5.73毫米汞柱;P = 0.025)。艾哈迈德组和贝尔维尔德组均需要进行青光眼药物治疗(分别为58.92%和71.67%)。两组的成功率相当。艾哈迈德组的完全成功和合格成功率为86.82%,失败率为13.17%。同样,贝尔维尔德组在87.75%的病例中显示完全成功和合格成功,12.25%的病例失败。在艾哈迈德组中,观察到11.97%的早期并发症、26.06%的晚期并发症和9.97%的再次手术。相比之下,在贝尔维尔德组中,观察到23.40%的早期并发症、30.95%的晚期并发症和11.70%的再次手术。
两组青光眼植入物均显示眼压显著降低,然而,贝尔维尔德植入物组的眼压降低幅度更大,但失败率和并发症比艾哈迈德植入物组更多。